AKBA Historical PE Ratio image   This AKBA PE ratio history page last updated 8/8/2022
AKBA Historical PE Ratio Chart
PeriodPriceAdj. EPSAnnualizedPE
Q2 2022
8/4/2022
0.410.230.920.4
Q1 2022
5/9/2022
0.34-0.35-1.40NA
Q4 2021
3/1/2022
2.15-0.40-1.60NA
Q3 2021
11/4/2021
3.04-0.34-1.36NA
Q2 2021
8/5/2021
2.87-0.51-2.04NA
Q1 2021
5/10/2021
2.90-0.45-1.80NA
Q4 2020
2/25/2021
3.47-0.60-2.40NA
Q3 2020
11/5/2020
2.49-0.42-1.68NA
Q2 2020
8/10/2020
10.67-0.44-1.76NA
Q1 2020
5/5/2020
11.95-0.47-1.88NA
Q4 2019
3/10/2020
7.43-0.79-3.16NA
Q3 2019
11/12/2019
3.33-0.46-1.84NA
Q2 2019
8/8/2019
4.17-0.25-1.00NA
Q1 2019
5/9/2019
5.92-0.44-1.76NA
Q4 2018
3/18/2019
8.17-0.76-3.04NA
Q3 2018
11/8/2018
8.20-0.46-1.84NA
Q2 2018
8/8/2018
9.72-0.60-2.40NA
Q1 2018
5/9/2018
9.51-0.48-1.92NA
Q4 2017
3/12/2018
13.520.251.0013.5
Q3 2017
11/8/2017
17.27-0.49-1.96NA
Q2 2017
8/8/2017
13.62-0.53-2.12NA
Q1 2017
5/9/2017
12.44-1.15-4.60NA
Q4 2016
3/6/2017
10.25-0.99-3.96NA
Q3 2016
11/9/2016
8.63-0.96-3.84NA
Q2 2016
8/9/2016
8.00-0.95-3.80NA
Q1 2016
5/5/2016
9.04-0.70-2.80NA
Q4 2015
3/14/2016
8.76-0.66-2.64NA
Q3 2015
11/9/2015
8.97-0.68-2.72NA
Q2 2015
8/11/2015
9.44-0.40-1.60NA
Q1 2015
5/11/2015
7.88-0.53-2.12NA
Q4 2014
3/4/2015
10.20-0.52-2.08NA
Q3 2014
11/10/2014
8.99-0.47-1.88NA
Q2 2014
8/11/2014
22.60-0.39-1.56NA
Q1 2014
5/12/2014
22.39-43.37-173.48NA
AKBA PE History Chart
PeriodPriceAdj. EPSTTMPE
Q2 2022
8/4/2022
0.410.23-0.86NA
Q1 2022
5/9/2022
0.34-0.35-1.60NA
Q4 2021
3/1/2022
2.15-0.40-1.70NA
Q3 2021
11/4/2021
3.04-0.34-1.90NA
Q2 2021
8/5/2021
2.87-0.51-1.98NA
Q1 2021
5/10/2021
2.90-0.45-1.91NA
Q4 2020
2/25/2021
3.47-0.60-1.93NA
Q3 2020
11/5/2020
2.49-0.42-2.12NA
Q2 2020
8/10/2020
10.67-0.44-2.16NA
Q1 2020
5/5/2020
11.95-0.47-1.97NA
Q4 2019
3/10/2020
7.43-0.79-1.94NA
Q3 2019
11/12/2019
3.33-0.46-1.91NA
Q2 2019
8/8/2019
4.17-0.25-1.91NA
Q1 2019
5/9/2019
5.92-0.44-2.26NA
Q4 2018
3/18/2019
8.17-0.76-2.30NA
Q3 2018
11/8/2018
8.20-0.46-1.29NA
Q2 2018
8/8/2018
9.72-0.60-1.32NA
Q1 2018
5/9/2018
9.51-0.48-1.25NA
Q4 2017
3/12/2018
13.520.25-1.92NA
Q3 2017
11/8/2017
17.27-0.49-3.16NA
Q2 2017
8/8/2017
13.62-0.53-3.63NA
Q1 2017
5/9/2017
12.44-1.15-4.05NA
Q4 2016
3/6/2017
10.25-0.99-3.60NA
Q3 2016
11/9/2016
8.63-0.96-3.27NA
Q2 2016
8/9/2016
8.00-0.95-2.99NA
Q1 2016
5/5/2016
9.04-0.70-2.44NA
Q4 2015
3/14/2016
8.76-0.66-2.27NA
Q3 2015
11/9/2015
8.97-0.68-2.13NA
Q2 2015
8/11/2015
9.44-0.40-1.92NA
Q1 2015
5/11/2015
7.88-0.53-1.91NA
Q4 2014
3/4/2015
10.20-0.52-44.75NA
Q3 2014
11/10/2014
8.99-0.47NANA
Q2 2014
8/11/2014
22.60-0.39NANA
Q1 2014
5/12/2014
22.39-43.37NANA
Quotes delayed 20 minutes

Email EnvelopeFree AKBA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Akebia Therapeutics (AKBA) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

AKRO PE Ratio History
AKUS PE Ratio History
AKYA PE Ratio History
ALBO PE Ratio History
ALDX PE Ratio History
ALEC PE Ratio History
ALGN PE Ratio History
ALGS PE Ratio History
ALHC PE Ratio History
ALIM PE Ratio History
How should the AKBA historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Akebia Therapeutics. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this AKBA Historical PE Ratio page.

What is the average historical PE for AKBA based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The AKBA historical PE ratio using the annualized quarterly earnings method works out to 7.0.

What is the average historical PE for AKBA based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The AKBA historical PE ratio using the TTM earnings method works out to NA.

On this page we presented the AKBA Historical PE Ratio information for Akebia Therapeutics' stock. The average AKBA historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 7.0. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average AKBA historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this AKBA historical PE result, against the recent PE: when this page was posted on 8/5/2022, the most recent closing price for AKBA had been 0.40, and the most recent quarterly earnings result, annualized, was 0.92. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent AKBA PE on 8/5/2022 based on annualized quarterly EPS was 0.4. Based on AKBA's history, that recent PE is low relative to the historical average, with the recent PE 94.3% lower than the historical average PE across our data set for Akebia Therapeutics.

For self directed investors doing their due diligence on AKBA or any other given stock, valuation analysis for AKBA can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Akebia Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for AKBA. Thanks for visiting, and the next time you need to research AKBA Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: MNTR Insider Buying, TLMD YTD Return, BBBY shares outstanding history.

 

AKBA Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.